Bayer's Missouri Courtroom Test Looms Over a Year of Quiet Portfolio Surgery

Bayer shares fell 3.3% as a Missouri glyphosate trial began, with a proposed settlement of up to $7.25 billion over 21 years awaiting a judge's ruling.

A fresh Roundup trial got underway this week in Missouri, and the timing could hardly be more delicate for Bayer. Three plaintiffs are taking on Monsanto, the group's US subsidiary, over allegations that the weedkiller was not adequately tested before it reached the market. Because the case is widely viewed as a bellwether for the glyphosate litigation still stacked up behind it, traders are watching closely — and they wasted little time reacting. Bayer shares shed 3.3% on the day the proceedings opened, closing at EUR 49.07.

The company rejects the claims. Its position is that glyphosate-based products are safe, and it has said it will keep cooperating with regulators as they revisit the science. That review is already moving: the EPA and the Department of Health and Human Services have agreed to broaden their joint work on the ongoing glyphosate assessment.

A Settlement Waiting in the Wings

What makes the Missouri hearing so consequential is that a proposed global settlement is already on the table. It would commit Bayer to payments of as much as USD 7.25 billion spread across 21 years. A hearing on that package was held roughly two weeks ago. If the judge declines to sign off, or sends it back for revisions, the company faces the prospect of years of individual trials with damage awards that are impossible to forecast.

That uncertainty remains the single biggest overhang for investors. Yet the equity has hardly behaved like a stock in distress. Since the start of the year it has gained 33%, and it currently trades at EUR 49.19. The 50-day moving average sits at EUR 48.61 — a level bulls would like to see hold.

Paying Down the Past, One Asset at a Time

While the courtroom drama plays out, management has been busy reshaping the balance sheet. On 21 September, Bayer agreed to sell the cancer drug Stivarga to Grünenthal in a deal worth up to EUR 375 million. Completion is targeted for late 2026 or early 2027. The logic is straightforward: free up cash, sharpen the pipeline's focus, and chip away at the debt pile left behind by the Monsanto acquisition.

Smaller disposals of this kind help at the margin, though they do not fundamentally alter the scale of the obligations. Investors are left weighing how quickly leverage can come down without starving the pharmaceutical business of the research spending it needs. That trade-off — near-term liquidity against long-term discovery power — has become the central question for how the DAX-listed group is valued.

Bayer has also been active on the funding side. A little over a week ago it placed hybrid bonds totaling EUR 2 billion, lifting the total outstanding volume of such subordinated instruments to EUR 6.55 billion.

Pipeline Wins Offer a Counterweight

The pharmaceutical story is not standing still. On Monday, the FDA granted priority review to Lynkuet, whose active ingredient is elinzanetant, for an additional indication covering vasomotor symptoms in patients undergoing endocrine therapy for breast cancer. That same day brought a procedural victory in Delaware, where a federal judge rejected motions from Pfizer, BioNTech and Moderna seeking dismissal of mRNA patent suits brought by Monsanto. Those cases can now proceed.

Clinical work is advancing too: Bayer has launched a global Phase II study of the investigational compound BAY 3670549 in adults with atrial fibrillation. And on 17 September, the FDA approved an expanded indication for the kidney drug Kerendia in chronic kidney disease associated with type 1 diabetes — the first new treatment option in that area for US patients in more than three decades.

The Operating Picture: Agriculture Strong, Pharma Soft

Second-quarter 2026 numbers, adjusted for currency and portfolio effects, showed revenue up 2.2% to EUR 10.872 billion. Crop Science did the heavy lifting, with adjusted earnings climbing 30.2%. The pharma division moved the other way, posting a 3.6% decline in adjusted earnings as patent expiries on key revenue drivers bite and put more pressure on newer launches such as Kerendia.

Hitting the full-year target of adjusted EBITDA between EUR 9.6 billion and EUR 10.1 billion — and core earnings per share of EUR 4.30 to EUR 4.90 — would go a long way toward validating the recovery narrative. So would a confirmed settlement in Missouri. The next major catalyst is the court's formal ruling on the settlement package, followed by the closing of the Stivarga sale by early 2027. Should the judge refuse to certify the deal, investors should brace for a re-rating of the legal risk — and for sharp moves in the share price.